Immunological features of EGFR-mutant non-small cell lung cancer and clinical practice: a narrative review.

71 In 10 cases of LUAD treated solely with osimertinib, the levels of CD40 (involved in antigen presentation) and CD83 (mediating cytotoxicity) on DCs showed an increasing trend. 72 Jia et al 73 demonstrated the dynamic impact of EGFR-TKIs (osimertinib and gefitinib) on the TME by a mouse model, showing an early anti-tumor immune response followed by late-stage immunosuppression.

also in 63,971 other papers